Cardio Diagnostics Holdings Inc(CDIO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 7:07 AM ET (Korea 9/29 20:07)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.91 | Insider Own | 4.34% | Shs Outstand | 3.0M | Perf Week | -1.36% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.8M | Perf Month | 1.27% |
| Enterprise Value | 0.00B | PEG | - | EPS next Q | - | Inst Own | 6.52% | Short Float | 0.19% | Perf Quarter | -8.95% |
| Income | -0.01B | P/S | 560.37 | EPS this Y | - | Inst Trans | -4.38% | Short Ratio | 0.09 | Perf Half Y | -3.62% |
| Sales | 0.00B | P/B | 0.75 | EPS next 5Y | - | ROA | -70.62% | Short Interest | 0.01M | Perf YTD | -30.12% |
| Book/sh | 2.51 | P/C | 1 | EPS past 3/5Y | 56.57% 30.61% | ROE | -75.44% | 52W High | -76.06% ($7.91) | Perf Year | -53.47% |
| Cash/sh | 1.89 | P/FCF | - | Sales past 3/5Y | 149.89% 101.4% | ROIC | -85.5% | 52W Low | 95.24% ($0.97) | Perf 3Y | -81.21% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 37.5% | Gross Margin | -2622.67% | Volatility(W/M) | 4.66% 6.3% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 38.37 | Sales Y/Y TTM | -25.92% | Oper. Margin | -44690.68% | ATR (14) | 0.13 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 17.15 | EPS Q/Q | 47.59% | Profit Margin | -44771.83% | RSI (14) | 46.73 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 17.15 | Sales Q/Q | -28.29% | SMA20 | -2.69% ($1.94) | Beta | 2.23 | Target Price | $60 |
| Payout | - | Debt/Eq | 0.05 | Earnings | - | SMA50 | 1.91% ($1.85) | Rel Volume | 0.18 | Prev Close | $1.95 |
| Employees | 15 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | - | SMA200 | -14.07% ($2.2) | Avg Volume(3M) | 0.06M | Price | $1.89 |
| IPO | 2022/1/14 | Option/Short | No/Yes | Trades | 90 | Volume | 10,345 | Change | -2.88% |
Cardio Diagnostics Holdings, Inc. is a precision medicine diagnostics company that combines artificial intelligence and epigenetics to enable the early detection and assessment of coronary heart disease (CHD). Founded in 2017 and headquartered in Chicago, Illinois, the company operates its business around its blood-based tests, Epi+Gen CHD and PrecisionCHD.
Over the past 1 year, on the lower side
76% below its 1-year high.
Traded less than usual That is 18% of its average volume.
CDIO has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $56,037. Peers typically go for $1,227.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 3 years ago, your return today would be -81.2%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 6.5%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
WARP VanEck Space ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #547 of 592 in the industry
Based on market cap of $6M.
LIMN#544 Liminatus Pharma Inc $6M PER - 
KAPA#545 Kairos Pharma Ltd $6M PER - 
ERNA#546 Ernexa Therapeutics Inc $6M PER - CDIO#547 Cardio Diagnostics Holdings Inc $6M PER - 
NCNA#548 NuCana plc ADR $6M PER - 
FAQ
What kind of company is CDIO?
CDIO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CDIO?
The market cap of CDIO is approximately $6M, ranking 5,664 within its sector.
What is the 52-week high and low for CDIO?
CDIO has recorded a 52-week high of $7.91 and a low of $0.97.
